AKEBIA THERAPEUTICS, INC. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
AKEBIA THERAPEUTICS, INC. (AKBA) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $2.88 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-08-05
- 2026-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $2.88M.
- 2026-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $3.55M.
- 2025-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $4.19M.
- 2025-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $4.80M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2026-06-30 | $2.88M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $3.55M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $4.19M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.80M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $5.38M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $5.93M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $4.26M 10-K · filed 2025-03-13 |
| 2024-09-30 | $4.60M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $4.92M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $5.16M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $317.00K 10-K · filed 2024-03-14 |
| 2022-12-31 | $922.00K 10-K/A · filed 2023-08-28 |
| 2022-09-30 | $1.05M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.84M 10-Q · filed 2022-08-04 |
| 2021-12-31 | $2.46M 10-K · filed 2022-03-01 |
| 2020-12-31 | $3.62M 10-K · filed 2021-02-25 |
| 2020-09-30 | $3.39M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $3.66M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $3.93M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $4.20M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |